选择性雌激素受体调节器 (SERMs):ER+乳腺癌治疗的进展,挑战和未来前景
Anurag Saini1, Ripunjay Kalita1, Tirtha Nath1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Guwahati, Assam, India.
Archiv der Pharmazie
|February 17, 2026
概括
新兴的异环药物为治疗雌激素受体阳性乳腺癌提供了新的希望,通过选择性向癌细胞,同时保持对骨和心血管系统的有益作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 选择性雌激素受体调节剂 (SERM) 对于治疗由雌激素驱动的乳腺癌至关重要.
- 在乳腺组织中,SERM 作用为雌激素对抗剂,但在骨和心血管系统 (CVS) 中则是激动剂.
- 雌激素受体阳性乳腺癌是全球最常见的亚型.
研究的目的:
- 提供超越传统支架的新兴异环 SERM 的综合分析.
- 将化学多样性与组织选择机制以及结构-活性关系联系起来.
- 突出克服局限性和改善治疗结果的创新策略.
主要方法:
- 对新兴的异环式SERM支架的审查 (英多尔,胺,氨酸,二烯,有机金属,植物雌激素衍生物).
- 组织选择机制和结构活动关系的分析.
- 整合结构,机械和治疗洞察力.
主要成果:
- 目前SERM的确定的局限性:不完全的选择性,代谢不稳定性,部分激动性和内分泌抵抗性.
- 突出显示了具有提高疗效潜力的新型异环 SERM.
- 讨论了克服抵抗和增强功效的创新策略.
结论:
- 新兴的异环式SERM代表了ER阳性乳腺癌治疗的有希望的途径.
- 解决抗性和选择性等局限性是优化临床结果的关键.
- 组合疗法和计算设计为改善治疗策略提供了途径.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
492
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
492


